<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02376309</url>
  </required_header>
  <id_info>
    <org_study_id>50679</org_study_id>
    <nct_id>NCT02376309</nct_id>
  </id_info>
  <brief_title>The Effect of Nandrolone Decanoate and Leucine on Muscle Loss</brief_title>
  <acronym>Le-Na</acronym>
  <official_title>The Effect of Nandrolone Decanoate Injection and Leucine Supplementation on Muscle Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A decrease in muscle mass can have a profound impact on quality of life, as it can lead to
      decreased strength, insulin resistance, lower basal metabolic rate and obesity. With this
      study we investigate whether ingesting leucine or getting a ND injection will reduce the loss
      of muscle mass and strength.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CSA Quadriceps (CT scan)</measure>
    <time_frame>7 days</time_frame>
    <description>CT scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle strength as measured by 1RM test</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle fiber type and CSA as measured by histochemistry from the muscle biopsy</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Muscle Atrophy</condition>
  <arm_group>
    <arm_group_label>Leu during inactivity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Leucine supplements</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ND during inactivity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nandrolone injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Inactivity</intervention_name>
    <description>Inactivity</description>
    <arm_group_label>Leu during inactivity</arm_group_label>
    <arm_group_label>ND during inactivity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ND</intervention_name>
    <description>1 nandrolone decanoate injection</description>
    <arm_group_label>ND during inactivity</arm_group_label>
    <other_name>Nandrolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Leu</intervention_name>
    <description>Leucine supplements</description>
    <arm_group_label>Leu during inactivity</arm_group_label>
    <other_name>Leucine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men 18-35 years

          -  BMI between 18.5 and 30 kg/m2

        Exclusion Criteria:

        - (Family) history of thromboembolic events

          -  Smoking

          -  Recent surgery (within 6 months prior to the study)

          -  Performing progressive resistance training more than three times per week in the past
             year

          -  Any back/leg/knee/shoulder complaints which may interfere with the use of crutches

          -  Current systemic use of corticosteroids, anabolic steroids, growth hormone,
             testosterone, nandrolone, protein supplements, immunosuppressants or insulin, blood
             sugar decreasing medication or EPO

          -  All co-morbidities interacting with mobility and muscle metabolism of the lower limbs
             (e.g. arthritis, spasticity/rigidity, all neurological disorders and paralysis)

          -  Use of anti-coagulants

          -  Pre-existing renal disease or those with a potential risk for renal dysfunction
             (diabetes, hypertension, reduced glomerular filtration rate)

          -  Liver disease

          -  Heart failure

          -  Migraine

          -  Allergy to nuts or soy

          -  High blood pressure (&gt;140 mmHg systolic and &gt;90 mmHg diastolic) In case of doubt, in-
             or exclusion of subject will be discussed with responsible physician or principal
             investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luc van Loon, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Centre+</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6200MD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2015</study_first_submitted>
  <study_first_submitted_qc>February 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decanoic acid</mesh_term>
    <mesh_term>Nandrolone</mesh_term>
    <mesh_term>Nandrolone decanoate</mesh_term>
    <mesh_term>Nandrolone phenpropionate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

